Valuation: Roche Holding AG

Market Cap 312B 381B 341B 285B 537B 35,782B 554B 3,761B 1,500B 19,092B 1,429B 1,398B 60,273B P/E 2026 *
21x
P/E 2027 * 18.9x
Enterprise Value 324B 395B 354B 296B 557B 37,126B 574B 3,902B 1,556B 19,810B 1,482B 1,451B 62,537B EV / Sales 2026 *
5.12x
EV / Sales 2027 * 4.8x
Free-Float
88.78%
Yield 2026 *
2.57%
Yield 2027 * 2.63%
Manager TitleAgeSince
Chief Executive Officer 51 14/03/2023
Director of Finance/CFO 59 05/06/2011
Chief Operating Officer - 30/09/2025
Director TitleAgeSince
Director/Board Member 68 31/12/1995
Chairman 59 14/03/2023
Director/Board Member 73 02/03/2015
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 384B
-0.79%-4.48%+44.44%+127.49% 1,216B
+1.43%+1.11%+47.73%+82.08% 656B
+1.07%-1.21%+32.99%+106.31% 509B
-0.36%-2.84%+47.23%+64.51% 384B
-0.14%-1.87%+71.05%+40.63% 362B
-0.78%+0.59%+31.01%+59.68% 311B
-0.80%+6.73%+11.89%+35.64% 293B
+0.03%-1.20%+45.89%+68.76% 249B
-0.41%-2.22%+35.24%+105.68% 208B
Average -0.38%+0.60%+40.83%+76.75% 465.31B
Weighted average by Cap. -0.30%+0.03%+42.47%+88.48%

Financials

2026 *2027 *
Net sales 63.25B 77.16B 69.21B 57.74B 109B 7,254B 112B 762B 304B 3,870B 290B 283B 12,218B 66.13B 80.68B 72.36B 60.37B 114B 7,584B 117B 797B 318B 4,047B 303B 296B 12,775B
Net income 14.82B 18.08B 16.21B 13.53B 25.49B 1,699B 26.29B 179B 71.22B 907B 67.86B 66.4B 2,863B 16.54B 20.18B 18.1B 15.1B 28.45B 1,897B 29.35B 199B 79.5B 1,012B 75.75B 74.12B 3,195B
Net Debt 11.72B 14.3B 12.83B 10.7B 20.16B 1,344B 20.8B 141B 56.34B 717B 53.68B 52.53B 2,265B 5.25B 6.41B 5.75B 4.79B 9.03B 602B 9.31B 63.29B 25.24B 321B 24.04B 23.53B 1,014B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Roche Holding AG